The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
The Spanish company will use the funding to accelerate the clinical transition of its LiverAce Combo assay for drug-induced liver injury assessment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback